320
Participants
Start Date
June 28, 2022
Primary Completion Date
July 30, 2027
Study Completion Date
July 30, 2027
GRC 54276
"Part 1a: GRC 54276 QD will be administered orally from Day 1 to Day 21 in a 21-day treatment cycle.~Part 2: GRC 54276 monotherapy therapy will commence after establishment of the MTD and/or RP2D for monotherapy arm."
GRC 54276 + Pembrolizumab
"Part 1b: GRC 54276 QD will be administered orally in combination with fixed dose of pembrolizumab IV every 21 days.~Part 2: GRC 54276 in combination with pembrolizumab will commence after establishment of the MTD and/or RP2D for combination therapy arm."
GRC 54276 + Atezolizumab
"Part 1b: GRC 54276 QD will be administered orally in combination with fixed dose of atezolizumab IV every 21 days.~Part 2: GRC 54276 in combination with atezolizumab will commence after establishment of the MTD and/or RP2D for combination therapy arm."
Carolina BioOncology Institute, Huntersville
Max Superspeciality Hospital, Delhi
Artemis Hospital, Gurgaon
PD Hinduja Hospital and Medical Research Centre, Mumbai
Bhaktivedanta Hospital and Research Institute, Thāne
HCG Manavata Cancer Centre, Nashik
Sankalp Hospital, Nashik
Krupamayi Hospitals, Aurangabad
AIG Hospitals, (A unit of asian Institute of Gastroenterology), Hyderabad
Basavatarakam Indo American Cancer Hospital Research Institute, Hyderabad
Hcg City Cancer Centre, Vijayawada
Mahatma Gandhi Cancer Hospital and Research Institute, Visakhapatnam
Cytecare Hospitals Pvt Ltd., Bengaluru
Vydehi Hospital, Bangalore
Aster CMI Hospital, Bengaluru
Malabar Cancer Centre, Kannur
Health Care Global Enterprises Ltd (HCG), Bangalore
Froedtert & Medical College of Wisconsin - Froedtert Hospital - Clinical Cancer Center, Milwaukee
Glenmark Specialty S.A.
INDUSTRY